In terms of valuation, Summit Therapeutics Inc’s market capitalization stands at $15.87 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...
Maky Zanganeh, Co-CEO of Summit Therapeutics' owns 5% of the biopharmaceutical company and stock options. One of the 34 ...
Bob Duggan’s success shows you don’t need a Ph.D., or even a college education, to make money in the complex world of biotech ...
Monday’s edition of Forbes Daily covers simmering conflict in the Middle East, the GOP’s embrace of cannabis, Adam Neumann’s latest venture in Saudi Arabia and more.
Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of ...
President Joe Biden told Indo-Pacific allies on Saturday that he believes China’s increasing military assertiveness is an effort to test the region at a turbulent moment for Beijing. Biden’s comments ...
UNITED NATIONS (AP) — Facing a swirl of conflicts and crises across a fragmented world, leaders attending this week’s annual ...
During HUAWEI CONNECT 2024, Huawei Cloud hosted a Summit themed "One Step to Intelligence, One Leap to Excellence", gathering ...
Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...
Summit Therapeutics and Akeso published results for the Phase III HARMONi-2 trial, which tested ivonescimab, a bispecific ...
Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback